Increased hepcidin in transferrin-treated thalassemic mice correlates with increased liver BMP2 expression and decreased hepatocyte ERK activation

Huiyong Chen, Tenzin Choesang, Huihui Li, Shuming Sun, Petra Pham, Weili Bao, Maria Feola, Mark Westerman, Guiyuan Li, Antonia Follenzi, Lionel Blanc, Stefano Rivella, Robert Fleming, and Yelena Ginzburg

Disclosures: Mark Westerman is an officer and shareholder of Intrinsic LifeSciences which developed the Murine Hepcidin CompeteTM kits used herein to measure serum hepcidin. The other authors have no conflicts of interest to disclose.

Contributions: H.C. collected and analyzed the data, designed the experiments, drafted and revised the manuscript. T.C. and S.S. collected and interpreted the data and revised the manuscript. H.L., P.P., W.B., M.F., and M.W. provided technical support and revised the manuscript. G.L. and A.F. provided logistical support and revised the manuscript. L.B. revised the manuscript. R.F. and S.R. provided logistical support, interpreted the data, and revised the manuscript. Y.G. developed the idea and designed the experiments, analyzed, and interpreted the data, drafted and revised the manuscript.